- Home
- LILAK vs CDTX Comparison
LILAK vs CDTX Comparison
Compare LILAK & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILAK
- CDTX
- Stock Information
- Founded
- LILAK 2017
- CDTX 2012
- Country
- LILAK Bermuda
- CDTX United States
- Employees
- LILAK N/A
- CDTX N/A
- Industry
- LILAK Cable & Other Pay Television Services
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LILAK Telecommunications
- CDTX Health Care
- Exchange
- LILAK Nasdaq
- CDTX Nasdaq
- Market Cap
- LILAK 1.1B
- CDTX 980.1M
- IPO Year
- LILAK N/A
- CDTX 2015
- Fundamental
- Price
- LILAK $7.13
- CDTX $63.37
- Analyst Decision
- LILAK Buy
- CDTX Strong Buy
- Analyst Count
- LILAK 3
- CDTX 11
- Target Price
- LILAK $10.27
- CDTX $52.11
- AVG Volume (30 Days)
- LILAK 1.5M
- CDTX 700.8K
- Earning Date
- LILAK 08-05-2025
- CDTX 08-07-2025
- Dividend Yield
- LILAK N/A
- CDTX N/A
- EPS Growth
- LILAK N/A
- CDTX N/A
- EPS
- LILAK N/A
- CDTX N/A
- Revenue
- LILAK $4,441,000,000.00
- CDTX $302,000.00
- Revenue This Year
- LILAK $2.45
- CDTX N/A
- Revenue Next Year
- LILAK $3.11
- CDTX N/A
- P/E Ratio
- LILAK N/A
- CDTX N/A
- Revenue Growth
- LILAK N/A
- CDTX N/A
- 52 Week Low
- LILAK $4.23
- CDTX $10.14
- 52 Week High
- LILAK $10.93
- CDTX $66.95
- Technical
- Relative Strength Index (RSI)
- LILAK 69.53
- CDTX 69.39
- Support Level
- LILAK $6.65
- CDTX $60.71
- Resistance Level
- LILAK $7.10
- CDTX $63.88
- Average True Range (ATR)
- LILAK 0.30
- CDTX 4.09
- MACD
- LILAK 0.01
- CDTX -0.46
- Stochastic Oscillator
- LILAK 97.11
- CDTX 72.97
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.